Subsequent Event

9 Months Ended

Sep. 30, 2011

Subsequent Event

Subsequent Event

Note 9. Subsequent Event

In October 2011, the Company executed an amendment to its agreement with Roche Molecular Systems, Inc. (“Roche”) for a nonexclusive license under a number of U.S. patents claiming nucleic acid amplification processes known as polymerase chain reaction, or PCR, homogeneous polymerase chain reaction, and reverse transcription polymerase chain reaction, or RT-PCR. The amendment, which is effective as of July 1, 2011, reduces the specified percentage of the Company’s applicable future net product revenues payable as royalty payments to Roche. During the three months ending December 31, 2011, the Company expects to recognize a $1.1 million reduction in license fee expense attributable to product revenues for the three months ended September 30, 2011.